Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. 295 patients from the SOLO2 trial ra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2022-04, Vol.165 (1), p.40-48
Hauptverfasser:	Trillsch, Fabian, Mahner, Sven, Ataseven, Beyhan, Asher, Rebecca, Aryal, Nanda, Dubot, Coraline, Clamp, Andrew, Penson, Richard T., Oza, Amit, Amit, Amnon, Huzarski, Tomasz, Casado, Antonio, Scambia, Giovanni, Friedlander, Michael, Colombo, Nicoletta, Fujiwara, Keiichi, Sonke, Gabe S., Denys, Hannelore, Lowe, Elizabeth S., Lee, Chee K., Pujade-Lauraine, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Age dependency Aged BRCA1 Protein - genetics Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - genetics Child, Preschool Female Humans Mutation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Olaparib Ovarian cancer Ovarian Neoplasms - chemically induced Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics PARP inhibitors Phthalazines - adverse effects Piperazines Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. 295 patients from the SOLO2 trial randomly assigned to olaparib or placebo were categorized according to age-cutoff at 65 years. Efficacy, tolerability, and quality of life (QoL) of olaparib relative to placebo within in each age group was analyzed. Baseline characteristics were similar in patients ≥65 years (N = 62;21.0%) compared to patients
ISSN:	0090-8258 1095-6859
DOI:	10.1016/j.ygyno.2022.01.024